Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis (RESOlVE)

A Prospective, Post-Market, Multicenter, Randomized Controlled Trial to Compare the Performance of the EndoRotor® System Versus Conventional Endoscopic Techniques for Direct Endoscopic Necrosectomy of Walled Off Necrosis - The RESOlVE Trial

In acute pancreatitis, approximately 20% of the cases result in severe necrotizing pancreatitis which is associated with significant morbidity and mortality. Necrotizing pancreatitis is characterized by the development of an acute necrotic collection and as this collection persists beyond 4 weeks, walled off necrosis (WON) encapsulates the collection. To date, this is treated by the step-up approach, which contains percutaneous drainage and minimally invasive video assisted retroperitoneal debridement (VARD) or endoscopic ultrasound (EUS) guided drainage followed by direct endoscopic necrosectomy (DEN). Different DEN techniques are available for the treatment of WON, however, there is a lack of effective endoscopic instruments to perform DEN. Recently, the first dedicated alternative to conventional DEN has been cleared for use, namely the EndoRotor® Resection System. This device is a powered mechanical debridement device intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. Previous (pilot and feasibility) studies showed promising results in terms of the amount of procedures, adverse events and length of hospital stay.

Therefore, aim of this study is to assess the performance of the EndoRotor, as compared to conventional endoscopic techniques, for direct endoscopic necrosectomy (DEN) of walled off necrosis (WON) in a randomized controlled trial.

Study Overview

• Status: Recruiting
• Conditions: Acute Pancreatitis; Necrosis; Pancreas, Acute (Infectious)
• Intervention / Treatment: Device: EndoRotor® System (Interscope, Inc., Northbridge, MA USA),; Procedure: Conventional endoscopic devices (according to standards of care)

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Marco Bruno, MD PhD; Phone Number: +31107035946; Email: m.bruno@erasmusmc.nl
• Study Contact Backup: Name: Charlotte van Veldhuisen, MD; Phone Number: +31204446303; Email: c.l.vanveldhuisen@amsterdamumc.nl

Study Locations

• Denmark
  • Hvidovre, Denmark
    • Active, not recruiting
    • Copenhagen University Hospital
• Germany
  • Düsseldorf, Germany
    • Recruiting
    • Evangelical Hospital
    • Contact: Dr. T Beyna
  • Frankfurt, Germany
    • Not yet recruiting
    • University of Frankfurt
    • Contact: Prof. Dr. Mireen Friedrich-Rust
• Italy
  • Milano, Italy
    • Not yet recruiting
    • Humanitas Reserach Hospital & Humanitas University
    • Contact: Prof. Dr. A. Repici
  • Roma, Italy
    • Not yet recruiting
    • Fondazione Policlinico Universitario Agostino Gemelli Irccs
    • Contact: Dr. A. Larghi
• Netherlands
  • Amsterdam, Netherlands
    • Recruiting
    • Amsterdam University Medical Center
    • Contact: Dr R.P. Voermans
  • Amsterdam, Netherlands, 1076JP
    • Not yet recruiting
    • Charlotte van Veldhuisen
    • Contact: Charlotte van Veldhuisen, MD; Phone Number: +31611295139; Email: c.l.vanveldhuisen@amsterdamumc.nl
  • Nieuwegein, Netherlands
    • Recruiting
    • St. Antonius Hospital
    • Contact: Dr. R. Verdonk
• United Kingdom
  • Manchester, United Kingdom
    • Not yet recruiting
    • Central Manchester University Hospital
    • Contact: Dr. J. Geraghty
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • Not yet recruiting
      • University of Alabama Medical Center
      • Contact: Dr. A. Ahmed
  • California
    • San Francisco, California, United States, 94110
      • Not yet recruiting
      • California Pacific Medical Center
      • Contact: Dr. K. Binmoeller
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Not yet recruiting
      • Thomas Jefferson University Hospital
      • Contact: Dr. T Kowalski

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with symptomatic pancreatic necrosis due to acute pancreatitis that have an indication to undergo endoscopic necrosectomy after having undergone EUS-guided drainage.

  a. Stent must be in place for a minimum of 2 days prior to the DEN procedure.

• Patients who can tolerate repeat endoscopic procedures.
• Subjects with the ability to understand the requirements of the study, who have provided written informed consent, and who are willing and able to return for the required follow-up assessments.
• ASA classification < 5.

Exclusion Criteria:

• Documented pseudoaneurysm > 1 cm within the WON.
• Subject unable or unwilling to provide informed consent.
• Intervening gastric varices or unavoidable blood vessels within the WON access tract (visible using endoscopy or endoscopic ultrasound).
• Coagulation disorders or anti-coagulant therapy which cannot be discontinued (aspirin allowed).
• Any condition that in the opinion of the Investigator would create an unsafe clinical situation or stent placement that would not allow the patient to safely undergo an endoscopic procedure.
• Pregnant or lactating women or women of childbearing potential who do not employ a reliable method of contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the duration of study participation.
• Patient is enrolled in another trial that could interfere with the endpoint analyses of this trial.
• Prior necrosectomy on existing collection.
• Greater than 2 pancreatic / extra-pancreatic fluid collections.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Interventional arm; Subjects randomized to the control device arm will undergo treatment with the EndoRotor System, which is a powered debridement tool intended for use in endoscopic procedures to resect and remove necrotic debris during direct endoscopic necrosectomy (DEN) for walled-off necrosis. The system consists of capital components including a power console, roll stand, vacuum pump, and foot control; as well as disposable components including a single-use catheter, purge kit, and suction bag. The EndoRotor System has CE-Mark 613797 and is cleared for use by the FDA in the United States.	Device: EndoRotor® System (Interscope, Inc., Northbridge, MA USA),; The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.
Active Comparator: Control arm; Subjects randomized to the control device arm will undergo conventional DEN as per the standard of care. Investigators will choose conventional DEN instruments according to their preference.	Procedure: Conventional endoscopic devices (according to standards of care); Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of DEN procedures required to achieve resolution of WON	Resolution is defined as clinical improvement of WON symptoms precluding the need for additional endoscopic or surgical interventions.; Clinical improvement is defined according to the criteria used in the PANTER trial and TENSION trial.8,15 "Clinical improvement" was defined as: i. Improved function of at least two organ systems (i.e. circulatory, pulmonary, renal) according to the Investigator's medical judgement within 72 hours, or; ii. At least 10% improvement of two out of three parameters of infection (i.e. C-reactive protein, leucocyte count or temperature) within 72 hours.	During a 6 month follow up period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	The occurrence of all adverse events measured from the Index Procedure through the 6 Month Post Necrosectomy Follow-up Visit	During a 6 month follow up period
Conversion to surgery defined as number of subject that require surgical intervention as a result of DEN failure as assessed by the Investigator during the index procedure through the 6 month post necrosectomy follow-up visit	In case of conversion to surgery, reason for conversion and type of surgical procedure	During a 6 month follow up period
Length of hospitalization	Length of hospitalization measured in days from the Index Procedure, including days in intensive care unit (ICU) vs. standard in-patient hospitalization	During a 6 month follow up period
Mean total cost of care per subject	Mean total cost of care per subject including: procedure costs, debridement devices used during the procedure, and inpatient hospital stay from the date of procedure to the date of discharge based on reimbursement fee structure expressed in US dollars, Euros or UK Pounds respectively. a. Procedure costs will be based on the cost of an endoscopic retrograde cholangiopancreatography (ERCP) which covers room, X-ray, sedation, personnel, and other materials.	During a 6 month follow up period
Percent reduction in WON collection volume (cm3)	Assessed by contrast enhanced computed tomography (CECT) scan or magnetic resonance imaging (MRI) (Baseline vs. completion of necrosectomy). Percent reduction in WON collection volume (cm3) as assessed by contrast enhanced computed tomography (CECT) scan or magnetic resonance imaging (MRI) (Baseline vs. completion of necrosectomy).; Endoscopic ultrasound (EUS) may be used for imaging only when a subject is contraindicated for MRI and CECT.; WON collection volume will be measured as follows: i. Length = longest diameter in cm/mm in the axial plane (left - right) ii. Width = the longest diameter in cm/mm (frontal - dorsal) in the same axial plane as the length, perpendicular on the longitudinal axis. iii. Height = longest diameter in cm/mm on coronal plane (cranial - caudal)	During a 6 month follow up period
Procedure time	Measured in minutes from the point of per-oral scope insertion to scope removal (scope-in / scope-out).	During a 6 month follow up period
Debridement time	Measured in minutes from the start of the debridement procedure to completion of the debridement procedure, including time to swap devices.	During a 6 month follow up period
Subject Quality of Life	Subject quality of life (QOL) as assessed by a SF-36 questionnaire performed at Baseline, Discharge, and at the 1, 3, and 6 Month Post Necrosectomy Follow-up Visits.	During a 6 month follow up period
The number of device deficiencies, defined as any inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance including malfunction, use errors, and inadequate labelingprocedure	Assessed by the Investigator during each DEN procedure. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer	During a 6 month follow up period

Collaborators and Investigators

• Sponsor: Erasmus Medical Center
• Collaborators: Interscope, Inc.
• Investigators: Principal Investigator: Marco Bruno, MD PhD, Erasmus Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): September 2, 2022
• Primary Completion (Estimated): February 28, 2024
• Study Completion (Estimated): August 30, 2024

Study Registration Dates

• First Submitted: March 18, 2021
• First Submitted That Met QC Criteria: March 23, 2021
• First Posted (Actual): March 24, 2021

Study Record Updates

• Last Update Posted (Actual): October 23, 2023
• Last Update Submitted That Met QC Criteria: October 19, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Pancreatic Diseases; Necrosis; Pancreatitis
• Other Study ID Numbers: CLIN-0061

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes